Reza Ghalehtaki: The Rapidly Evolving Role of NaSRT in the Management of Brain Metastases
Reza Ghalehtaki, Vice Dean of Research Affairs at the Department of Radiation Oncology and Associate Professor at Tehran University of Medical Sciences, shared a post on LinkedIn about a paper he co-authored with colleagues, published in Discover Oncology:
“New Article Alert!
Happy to share our recent publication, ‘Neoadjuvant stereotactic radiotherapy for brain metastasis: a review of ongoing clinical trials’ in ‘Discover Oncology’.
This comprehensive review explores the rapidly evolving role of neoadjuvant stereotactic radiotherapy (NaSRT) in the multidisciplinary management of brain metastases.
Why does this matter?
With the increasing incidence of brain metastases in cancer patients, innovation in treatment strategies is key. The review systematically analyzes 18 current clinical trials investigating NaSRT, highlighting:
- Diverse trial designs and inclusion criteria,
- Endpoints such as local control, systemic therapy integration, and reduction in leptomeningeal disease and radiation necrosis,
- The urgent need for standardized protocols to facilitate comparison and clinical adoption.
Key takeaway:
NaSRT may soon shift the paradigm in brain metastasis treatment, improving patient outcomes and quality of life. But, as underlined by this review, defining indications and careful patient selection, collaborative research and protocol harmonization remain critical.
I want to sincerely thank my co-authors, Nikan Amirkhani, Alba Fiorentino, Paola Anna Jablonska, Chunn Ehsan Saraee, and Dr. Zeinalizadeh for their dedication, insights, and teamwork on this project.
Collaborating with such talented colleagues is always a privilege.”
Alba Fiorentino, Director of the Diagnostic and Therapeutic Department and Director of the Miulli Oncology Radiation Therapy Unit at Ecclesiastical Institution of the F. Miulli Regional General Hospital, shared this post, adding:
“A new treatment approach involving radiosurgery or stereotactic radiotherapy as a neoadjuvant to surgery may soon be available for patients with brain metastasis.
Grateful to Reza Ghalehtaki, MD, for this collaboration.”
Title: Neoadjuvant stereotactic radiotherapy for brain metastasis: a review of ongoing clinical trials
Authors: Nikan Amirkhani, Ehsan Saraee, Mehdi Zeinalizadeh, Alba Fiorentino, Paola Anna Jablonska, Reza Ghalehtaki
You can read the Full Article on Discover Oncology.
More posts featuring Reza Ghalehtaki on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023